Inhibitor Report for: 6QAC-HUT IC50 6.2 nM for human BChE Residual activity of 58% for human AChE. Compound 8 of the paper Meden et al. derived from Tryptophan General
Type Derivative of Tryptophan , Indole Chemical_Nomenclature (2S)-2-(butylamino)-N-(3-cycloheptylpropyl)-3-(1H-indol-3-yl)propanamide Canonical SMILES CCCCNC(CC1=CNC2=CC=CC=C21)C(=O)NCCCC3CCCCCC3 InChI InChI=1S/C25H39N3O/c1-2-3-16-26-24(18-21-19-28-23-15-9-8-14-22(21)23)25(29)27-17-10-13-20-11-6-4-5-7-12-20/h8-9,14-15,19-20,24,26,28H,2-7,10-13,16-18H2,1H3,(H,27,29)/t24-/m0/s1 InChIKey UWVIHWQBZNJHCM-DEOSSOPVSA-N Other name(s) HUT
________________________________________________________________________________________________
Target
Families | 6QAC-HUT ligand of proteins in family: BCHE Stucture | 1 structure : 6QAC : Human Butyrylcholinesterase in complex with (S)-2-(butylamino)-N-(3-cycloheptylpropyl)-3-(1H-indol-3-yl)propanamide Protein | human-BCHE
References:
Search PubMed for references concerning:
6QAC-HUT
Title: Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's diseaseMeden A , Knez D , Jukic M , Brazzolotto X , Grsic M , Pislar A , Zahirovic A , Kos J , Nachon F and Groselj U <2 more author(s)> Meden A , Knez D , Jukic M , Brazzolotto X , Grsic M , Pislar A , Zahirovic A , Kos J , Nachon F , Svete J , Gobec S , Groselj U (- 2) Ref: Chem Commun (Camb), 55 :3765, 2019 : PubMed Abstract ESTHER: Meden_2019_Chem.Commun.(Camb)_55_3765 PubMedSearch: Meden 2019 Chem.Commun.(Camb) 55 3765 PubMedID: 30864579 Gene_locus related to this paper: human-BCHE Inhibitor(s) related to this paper: 6QAD-HUZ ,
6QAE-HUK ,
6QAC-HUT ,
6QAB-HUQ ,
6QAA-HUN Abstract
We have identified tryptophan-based selective nanomolar butyrylcholinesterase (BChE) inhibitors. They are defined according to their chemical modularity, novel binding mode revealed by five solved crystal structures with human BChE, low cytotoxicity, and predicted permeability of the blood-brain barrier. Altogether, these factors indicate their potential as unique lead compounds for symptomatic therapy against Alzheimer's disease.
